Through Baylor College of Medicine, this prospective, open-label, randomized two-arm multi-center study focuses on pediatric patients between the ages of 1 years of age – less than 18 years of age, who are newly diagnosed with ITP. Participants will be randomized into groups to receive either eltrombopag or one of three typical first-line ITP therapies. For those in the eltrombopag group, participants can expect to receive this drug for twelve weeks with the option to continue up to one year, depending on their response to the drug. The goal of this study is to determine if platelet counts in pediatric patients with ITP respond better to eltrombopag versus standard first-line therapies.
USA
Recruiting
